380 related articles for article (PubMed ID: 32576229)
1. Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials.
Stauffer VL; Turner I; Kemmer P; Kielbasa W; Day K; Port M; Quinlan T; Camporeale A
J Headache Pain; 2020 Jun; 21(1):79. PubMed ID: 32576229
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
Bangs ME; Kudrow D; Wang S; Oakes TM; Terwindt GM; Magis D; Yunes-Medina L; Stauffer VL
BMC Neurol; 2020 Jan; 20(1):25. PubMed ID: 31952501
[TBL] [Abstract][Full Text] [Related]
3. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.
Förderreuther S; Zhang Q; Stauffer VL; Aurora SK; Láinez MJA
J Headache Pain; 2018 Dec; 19(1):121. PubMed ID: 30594122
[TBL] [Abstract][Full Text] [Related]
4. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
Ailani J; Andrews JS; Rettiganti M; Nicholson RA
J Headache Pain; 2020 Oct; 21(1):123. PubMed ID: 33069214
[TBL] [Abstract][Full Text] [Related]
5. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
Ament M; Day K; Stauffer VL; Skljarevski V; Rettiganti M; Pearlman E; Aurora SK
J Headache Pain; 2021 Feb; 22(1):6. PubMed ID: 33549036
[TBL] [Abstract][Full Text] [Related]
6. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
9. Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials.
Stauffer VL; Wang S; Voulgaropoulos M; Skljarevski V; Kovacik A; Aurora SK
Headache; 2019 Jun; 59(6):834-847. PubMed ID: 30942898
[TBL] [Abstract][Full Text] [Related]
10. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.
Camporeale A; Kudrow D; Sides R; Wang S; Van Dycke A; Selzler KJ; Stauffer VL
BMC Neurol; 2018 Nov; 18(1):188. PubMed ID: 30413151
[TBL] [Abstract][Full Text] [Related]
11. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
Detke HC; Goadsby PJ; Wang S; Friedman DI; Selzler KJ; Aurora SK
Neurology; 2018 Dec; 91(24):e2211-e2221. PubMed ID: 30446596
[TBL] [Abstract][Full Text] [Related]
12. Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials.
Kuruppu DK; North JM; Kovacik AJ; Dong Y; Pearlman EM; Hutchinson SL
Adv Ther; 2021 Mar; 38(3):1614-1626. PubMed ID: 33544305
[TBL] [Abstract][Full Text] [Related]
13. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine.
Dodick DW; Doty EG; Aurora SK; Ruff DD; Stauffer VL; Jedynak J; Dong Y; Pearlman EM
Cephalalgia; 2021 Mar; 41(3):340-352. PubMed ID: 33143451
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies.
Smitherman TA; Tietjen GE; Schuh K; Skljarevski V; Lipsius S; D'Souza DN; Pearlman EM
Headache; 2020 Nov; 60(10):2202-2219. PubMed ID: 33063862
[TBL] [Abstract][Full Text] [Related]
16. Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis.
Pozo-Rosich P; Samaan KH; Schwedt TJ; Nicholson RA; Rettiganti M; Pearlman EM
Adv Ther; 2021 Jun; 38(6):3154-3165. PubMed ID: 33950375
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies.
Oakes TM; Kovacs R; Rosen N; Doty E; Kemmer P; Aurora SK; Camporeale A
Headache; 2020 Jan; 60(1):110-123. PubMed ID: 31721185
[TBL] [Abstract][Full Text] [Related]
19. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.
Jedynak J; Eross E; Gendolla A; Rettiganti M; Stauffer VL
J Headache Pain; 2021 May; 22(1):48. PubMed ID: 34049484
[TBL] [Abstract][Full Text] [Related]
20. Benefit-Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm.
Citrome L; Sánchez Del Rio M; Dong Y; Nichols RM; Tockhorn-Heidenreich A; Foster SA; Stauffer VL
Adv Ther; 2021 Aug; 38(8):4442-4460. PubMed ID: 34264500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
